Merck & Co., Inc. (NYSE:MRK) Share Price Breaks Below Fifty Day Moving Average Following Insider Selling

Merck & Co., Inc. logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Merck shares fell below their 50-day moving average, trading as low as $144.25 versus the average of $146.04.
  • EVP Richard Deluca sold 58,185 shares for about $8.6 million, reducing his direct ownership by 34%.
  • Analysts maintain a Moderate Buy consensus with an average price target of $155.74; Merck also beat quarterly estimates, reporting EPS of $2.49 and revenue of $18.09 billion.
  • Five stocks we like better than Merck & Co., Inc..

Merck & Co., Inc. (NYSE:MRK - Get Free Report)'s share price crossed below its 50 day moving average during trading on Monday after an insider sold shares in the company. The stock has a 50 day moving average of $146.04 and traded as low as $144.25. Merck & Co., Inc. shares last traded at $144.4870, with a volume of 8,610,678 shares changing hands.

Specifically, EVP Richard Deluca sold 58,185 shares of the business's stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $148.01, for a total value of $8,611,961.85. Following the sale, the executive vice president directly owned 112,955 shares in the company, valued at $16,718,469.55. The trade was a 34.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Analyst Ratings Changes

MRK has been the topic of a number of recent research reports. Cantor Fitzgerald lifted their target price on Merck & Co., Inc. from $145.00 to $155.00 and gave the company a "neutral" rating in a research report on Monday, November 2nd. Barclays boosted their target price on Merck & Co., Inc. from $150.00 to $180.00 and gave the company an "overweight" rating in a research note on Monday, October 26th. Jefferies Financial Group upped their price target on Merck & Co., Inc. from $152.00 to $175.00 and gave the stock a "buy" rating in a research report on Thursday, August 20th. The Goldman Sachs Group raised their price target on shares of Merck & Co., Inc. from $140.00 to $160.00 and gave the stock a "buy" rating in a research note on Friday, August 21st. Finally, BMO Capital Markets raised their price target on shares of Merck & Co., Inc. from $142.00 to $170.00 and gave the stock an "outperform" rating in a research note on Thursday, August 20th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $155.74.

Check Out Our Latest Analysis on MRK

Merck & Co., Inc. Stock Performance

The stock's 50 day moving average price is $146.04 and its 200 day moving average price is $128.80. The company has a current ratio of 1.35, a quick ratio of 1.14 and a debt-to-equity ratio of 1.11. The company has a market capitalization of $356.20 billion, a price-to-earnings ratio of 148.96, a P/E/G ratio of 6.74 and a beta of 0.13.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last released its earnings results on Thursday, October 29th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.09 by $0.40. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 3.64%. The business had revenue of $18.09 billion for the quarter, compared to the consensus estimate of $17.33 billion. During the same quarter in the previous year, the business earned $2.58 earnings per share. Merck & Co., Inc.'s quarterly revenue was up 4.7% on a year-over-year basis. Analysts expect that Merck & Co., Inc. will post 2.82 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Round Rock Advisors LLC increased its stake in Merck & Co., Inc. by 0.7% during the 2nd quarter. Round Rock Advisors LLC now owns 9,901 shares of the company's stock valued at $1,272,000 after purchasing an additional 66 shares in the last quarter. Cypress Wealth Services LLC raised its holdings in Merck & Co., Inc. by 0.5% during the third quarter. Cypress Wealth Services LLC now owns 13,807 shares of the company's stock worth $1,960,000 after buying an additional 69 shares during the last quarter. Code Waechter LLC raised its holdings in Merck & Co., Inc. by 3.4% during the third quarter. Code Waechter LLC now owns 2,179 shares of the company's stock worth $317,000 after buying an additional 71 shares during the last quarter. Quest 10 Wealth Builders Inc. lifted its stake in shares of Merck & Co., Inc. by 12.2% in the third quarter. Quest 10 Wealth Builders Inc. now owns 699 shares of the company's stock valued at $102,000 after buying an additional 76 shares in the last quarter. Finally, Cascade Financial Partners LLC lifted its stake in shares of Merck & Co., Inc. by 0.5% in the second quarter. Cascade Financial Partners LLC now owns 14,746 shares of the company's stock valued at $1,895,000 after buying an additional 80 shares in the last quarter. Institutional investors and hedge funds own 76.07% of the company's stock.

About Merck & Co., Inc.

(Get Free Report)

Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company's research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Merck & Co., Inc. Right Now?

Before you consider Merck & Co., Inc., you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck & Co., Inc. wasn't on the list.

While Merck & Co., Inc. currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines